LEP and obesity due to melanocortin 4 receptor deficiency: Some of these treatments could be therapies to target leptin or its receptors, and may also be tested in clinical trials for asthmatic patients with not only obesity, but also other leptin-related pathologies, including (but not limited to) cardiovascular diseases, diabetes mellitus, or rheumatoid arthritis, which have already been associated with asthma [67,68,69].